Nerves run through almost every solid tumor, yet we rarely think of nerve damage as something that changes how the immune system sees cancer. A 2025 open-access study in the Journal of Experimental & Clinical Cancer Research changes that picture. It pinpoints a single molecule released by injured nerves — neurofilament light chain (NEFL, also written NFL or NfL) — as the signal that reprograms tumor-associated macrophages and lets breast tumors escape immune attack.
The question: does nerve injury change anti-tumor immunity?
Surgery, chemotherapy, and the tumor itself can all damage the peripheral nerves around a tumor. Clinicians have long observed that nerve damage tends to track with worse outcomes in solid tumors, but the reason was unclear. Jiang, Zeng, Feng, Deng and colleagues at Sun Yat-Sen Memorial Hospital set out to test a direct hypothesis: that injured nerves actively reshape the tumor immune environment.
Mining the TCGA-BRCA dataset together with their own clinical breast-cancer samples, the team found that markers of peripheral nerve injury were associated with poor prognosis and with signs of immune evasion. That clinical signal motivated the mechanistic work that followed.
How the study was done
The authors built the case step by step, first in living tumors and then in controlled co-culture:
- Orthotopic mouse breast-cancer models, where sympathetic nerves were damaged chemically with 6-OHDA (a classic sympathetic denervation agent), or nerve lysate was injected directly into the tumor.
- Mass-spectrometry screening of the nerve lysate to find which component carried the pro-tumor activity — this is how NEFL/NFL was identified as the lead candidate.
- Tumor immune profiling by flow cytometry, multiplex immunohistochemistry, and single-cell RNA sequencing (scRNA-seq) to see which cells changed and how.
- In vitro co-culture of macrophages with CD8⁺ T cells, plus transcriptomic profiling, to connect NEFL to a specific signaling pathway.
The key finding: NEFL is the effector molecule
Both 6-OHDA denervation and nerve-lysate injection accelerated tumor growth, confirming that it is nerve damage — not simply the presence of nerves — that drives progression. scRNA-seq showed why: nerve injury increased the proportion of tumor-associated macrophages (TAMs), both by making them proliferate and by recruiting more of them into the tumor.
When the nerve lysate was fractionated and screened by mass spectrometry, neurofilament light chain (NEFL/NFL) emerged as the active component. The proof was functional: injecting recombinant NFL directly into the tumor reproduced the full effect of nerve damage — the same TAM expansion and the same acceleration of tumor growth seen with 6-OHDA and nerve lysate.
How NEFL helps tumors hide: TAMs, CD8⁺ T cells, and NF-κB
The downstream mechanism links macrophages to T-cell failure. NEFL-activated macrophages released factors that pushed CD8⁺ cytotoxic T cells into senescence — a dysfunctional, exhausted-like state in which they can no longer kill tumor cells effectively. Transcriptomic analysis traced this to activation of the NF-κB signaling pathway, and the authors confirmed the link by blocking NF-κB with the inhibitor BAY 11-7082, which prevented the T-cell senescence in vitro.
Peripheral nerve injury → release of NEFL/NFL → TAM proliferation & recruitment → NF-κB activation in macrophages → CD8⁺ T-cell senescence → immune evasion & faster breast-tumor growth.
Why it matters
This work reframes peripheral nerve injury as an active driver of immune escape, not a passive bystander. Because the effect runs through a defined molecule (NEFL) and a defined pathway (NF-κB), each step is a potential intervention point. The authors propose neuroprotection — limiting nerve damage during treatment — as a strategy to preserve anti-tumor immunosurveillance. NEFL/NfL is also already an established blood biomarker of neuronal injury, which makes it attractive both as a readout and as a target for further study.
Why it matters for your bench: the study rests on two NEFL tools you can source directly — recombinant NFL to deliver the effector molecule, and an NFL ELISA to quantify it in tissue or fluid.
Reproduce or extend this workflow with BioHippo reagents
If you want to test the NEFL–macrophage axis in your own model, these two research-grade (RUO) reagents map onto the study’s core steps.
Recombinant Mouse Neurofilament Light Polypeptide (Nefl)
The effector molecule itself — deliver recombinant mouse NFL in vitro or intratumorally, as used to drive TAM proliferation in the study.
- Yeast (S. cerevisiae) expressed, N-terminal 6×His tag
- Purity >90% (SDS-PAGE) · MW 63.4 kDa
- UniProt P08551 (mouse Nefl) · Cat. CSB-YP015688MO · RUO
Mouse NEFL (Neurofilament, Light Polypeptide) ELISA Kit
Quantify the readout — measure NFL in tumor lysate, serum, plasma, or CSF, the way the study tracked elevated NFL after nerve injury.
- Sandwich ELISA · reactivity: mouse
- Detection range 15.63–1000 pg/mL · sensitivity 6.3 pg/mL
- Serum, plasma, CSF & other fluids · ~3.5 h · Cat. ELK6650
Need a different species? BioHippo also stocks human, rat, and other NEFL ELISA kits for translational and biomarker work.
Reference
Jiang Y, Zeng W, Feng Y, Deng X, Wang J, et al. Peripheral nerve injury-induced remodeling of the tumor-associated macrophages promotes immune evasion in breast cancer. Journal of Experimental & Clinical Cancer Research 2025;44:280. Open access (CC BY 4.0). https://doi.org/10.1186/s13046-025-03545-x
Products are For Research Use Only. Not for use in diagnostic or therapeutic procedures. This article summarizes independent, peer-reviewed research for educational purposes; BioHippo is not affiliated with the authors, and the cited reagents were not necessarily the specific catalog items used by the study authors.
